Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene Food Effect and DDI Study
NCT04829773Phase 1Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of palovarotene in fibrodysplasia ossificans progressiva (FOP) (4 cohorts), sponsored by Clementia Pharmaceuticals Inc. Primary endpoints: Maximum (peak) observed plasma drug concentration, Time to reach maximum (peak) observed plasma concentration and 12 more. Started Jan 2019; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT04829773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829773.